FDA Approves First-in-Human Trial for New Targeted Cancer Therapy

Vivos Inc. has received FDA approval to commence a first-in-human clinical feasibility study in the U.S. for its innovative RadioGel® therapy. This yttrium-90-based injectable hydrogel aims to provide targeted treatment for cancerous tumors. The initial study will focus on assessing the safety and feasibility of the treatment in patients with non-resectable papillary thyroid carcinoma at Mayo Clinic.